Press releases
-
-
ProQR Announces First Quarter 2021 Operating and Financial Results
- ProQR Therapeutics
- $PRQR
- PRQR
- Biotechnology
- Rare Disease
- RNA Therapies
-
-
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
- ProQR Therapeutics
- Sepofarsen
- Leber Congenital Amaurosis
- Ophthalmology
- Biotechnology
- ARVO
-
ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
- ProQR Therapeutics
- PRQR
- $PRQR
-
ProQR Announces Annual Meeting of Shareholders
- Annual General Meeting
- ProQR Therapeutics
- ProQR
- PRQR
-
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
- Sepofarsen
- Clinical Trial
- Leber Congenital Amaurosis
- LCA10
- Ophthalmology
- Biotechnology
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Ophthalmology
- Inherited Retinal Diseases
-
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
- Sepofarsen
- Leber Congenital Amaurosis
- AAPOS
- Inherited Retinal Diseases
-
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
- Inherited Retinal Diseases
-
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
- Inherited Retinal Diseases
-
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
- QR-421a
- Usher Syndrome
- NsRP
- Clinical Trial
- Inherited Retinal Diseases
-
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
- QR-421a
- Usher Syndrome
- Retinitis Pigmentosa
- NsRP
- RNA Therapies
- Rare Disease
- Inherited Retinal Diseases
-
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
- Event
- Investor Conference
- Biotechnology
-
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
- Biotechnology
- Inherited Retinal Diseases
- RNA Therapies
- Daniel A. De Boer
- Financial Results
-
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
- QR-421a
- Usher syndrome
- Usher Syndrome
- QR-421a
- Paul Yang
- MD
- PhD
- Event
- Inherited Retinal Diseases
-
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
- Sepofarsen
- LCA10
- Clinical Trial
- Inherited Retinal Diseases
- Leber Congenital Amaurosis
-
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
- Event
- Investor Conference
-
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
- Investor Conference
- Event
-
ProQR Announces Third Quarter 2020 Operating and Financial Results
- Ophthalmology
- Biotechnology
- RNA Therapies
- Sepofarsen
- QR-421a
- QR-1123
- Leber Congenital Amaurosis
- Retinitis Pigmentosa
- Financial Results
-
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
- Sepofarsen (QR-110)
- Leber congenital amaurosis
- Sepofarsen
- AAO
- LCA10
- Ophthalmology
- Biotechnology
- Leber Congenital Amaurosis
-
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
- Chief Scientific Officer
- Management
- Biotechnology
- Leadership
- Ophthalmology
- Naveed Shams
- MD
- PhD
-
ProQR Announces Virtual Presentations at Scientific Conferences
- Euretina
- AAOpt
- Sepofarsen
- Leber Congenital Amaurosis
- LCA10
- Biotechnology
- Drug Development
- Ophthalmology
-
ProQR to Participate in Upcoming Investor Conferences
- Biotechnology
- RNA Therapies
- Ophthalmology
- Inherited Retinal Diseases
-
ProQR Announces Second Quarter 2020 Operating and Financial Results
- Ophthalmology
- Biotechnology
- RNA Therapies
- Sepofarsen
- QR-421a
- QR-1123
- Leber Congenital Amaurosis
- Retinitis Pigmentosa